Purpose: We have previously reported changes in retinal function and histopathology in rabbits treated with vigabatrin. The purpose of the present study was to evaluate retinal function and histopathology of retina in rabbits 4-5 months after terminating vigabatrin medication. Methods: Five rabbits were treated with a daily per oral dose of vigabatrin during 12-13 months. After terminating treatment an observation period of 4-5 months followed. Six rabbits receiving water served as controls. Standardized full-field electroretinograms were performed every 6-8 weeks, using a Burian-Allen bipolar contact lens. After 18 months the rabbits were sacrificed and the morphology of the sectioned retina was studied. The antibodies used for staining were GABA, GFAP, GAD, and vimentin. Results: After 12-13 months of treatment the full-field ERG was reduced in all rabbits treated with vigabatrin. There was a statistically significant difference in the dark adapted cone b-wave amplitude between treated animals and controls (Wilcoxon signed-rank test, p = 0.043). This difference was consistent also 4-5 months after terminating treatment. Immunohistology of the sectioned retina demonstrated no significant difference in immunoreactivity between treated animals and controls. All treated rabbits demonstrated elevated serum concentration of the drug during medication. Conclusion: Four to five months after terminating treatment with vigabatrin the rabbit full-field ERG remains reduced in isolated cone b-wave amplitude indicating that vigabatrin induced retinal dysfunction may be irreversible. However, immunohistology is normal after a period without treatment, implying that the previously described changes in retinal morphology and glial cell activity are reversible, and probably exist only during treatment.
Introduction
In 1997 the first reports were presented of severe, persistent visual field defects associated with the use of vigabatrin, an antiepileptic drug that is still used for treating seizures in patients with complex epilepsy and in children with infantile spasm [1] [2] [3] [4] [5] [6] . As approximately 30-40% [7] [8] [9] of adult patients receiving vigabatrin develop visual field defects, we suspect that also children treated with this drug may do so, however, visual field testing in children under 10-12 years of age is problematic and unreliable. We have therefore previously recommended electroretinography as an objective and reliable method for monitoring these patients, as the visual field defect correlates well with a reduced retinal function assessed with the full-field electroretinogram (ERG) [10] . This finding has been confirmed by other research groups [8, [11] [12] [13] .
The mechanism of action of vigabatrin involves the inhibition of the c-aminobutyric acid (GABA) transaminase enzyme, leading to increased levels of GABA in the brain. GABA is an important modulatory neurotransmitter. A previous report has demonstrated that vigabatrin in rabbit retina causes changes in immunohistopathology characterized by an enhancement of the glial cells located in the peripheral parts of the retina, which may explain the concentric visual field defect found in patients taking the drug [14] . These changes in immunohistopathology were also correlated with a reduced cone b-wave amplitude in the rabbit full-field ERG, a result very similar to the reduced ERG in vigabatrin treated patients.
Several clinical studies have previously been conducted aiming to determine whether the vigabatrin caused visual field defect is irreversible or not. Most of these studies have demonstrated neither improvement nor worsening 1-47 months after treatment was stopped, suggesting that the visual field defect is irreversible but not progressive [15] [16] [17] [18] [19] [20] [21] . In addition, some of these investigators have assessed ERGs, which showed irreversible changes [15, 17, 18, 21] . The most consistent ERG results were a reduction in photoptic b-wave amplitude, a reduction in amplitudes of the oscillatory potentials and a reduction in amplitudes of the 30 Hz flicker ERG. Some investigations also showed a reduction in the scotopic b-wave amplitude [15, 17] .
There are, however a few studies indicating some reversibility. In a recent study Fledelius [22] found a significant improvement, but not full recovery, in the visual fields of patients 6-26 months after full drug withdrawal. Similar results have been reported by Krakow et al. [23] . A recent study [24] has shown increased amplitudes in both photopic and scotopic oscillatory potentials after discontinuation of vigabatrin, but they interpret these changes as a non-toxic pharmacological effect of vigabatrin on GABAergic amacrine cells in the inner retina.
Thus, it is still not clarified whether vigabatrin caused changes in retinal function and histology are reversible or not. The aim of the present study was therefore to investigate if rabbit retina improves in function and histology several months after terminating treatment with vigabatrin.
Material and methods

Subjects and medication
Seven rabbits, nine months of age at entry to the study, were treated with a daily per oral dose of vigabatrin during 12-13 months. The doses of medication ranged between 250 and 1250 mg and had to be continuously adjusted since some of the rabbits suffered from serious drug side effects (loss of appetite), when receiving high doses of vigabatrin. The medication was administrated orally as a water solution, using a syringe. Once a month, blood samples were collected from the ear vein of all the rabbits to measure the serum concentration of vigabatrin in order to ensure proper medication. After terminating treatment an observation period of 4-5 months followed. Nine rabbits receiving water served as controls and were examined according to the protocol used for the treated rabbits. Two treated rabbits and three controls died unexpectedly during the study and were therefore excluded. The study was conducted with approval of the ethical committee for animal research at the University of Lund. The research procedures were in accordance with the ARVO statement for the use of animals in ophthalmic and vision research.
On entry to the study all rabbits were examined with standardized full-field ERG [25] , on three separate occasions before randomization. After randomization and initiation of treatment, full-field ERGs were performed every 4-8 weeks. Medication was carried out during 12-13 months and then discontinued. The rabbits were further followed regularly with full-field ERG for another 4-5 months.
After 18 months the rabbits were sacrificed and the morphology of the sectioned retina was studied.
Electrophysiology
Full-field ERGs were recorded with a Nicolet analysis system (Nicolet Biomedical Instruments, Madison Wisconsin) as described previously [14] . The examinations were conducted according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standards [26] . The right eye was tested after maximal pupil dilation with topical 1% cyclopentolate hydrochloride, and after at least 30 min of dark adaptation. A Burian-Allen bipolar ERG contact lens electrode was applied on the topically anesthetized cornea together with a subcutaneous ground electrode on the neck. Responses were obtained with a wide band filter ()3 dB at 1and 500 Hz), stimulating . The referred luminance of the four different light stimuli has been measured on the light reflected from the Ganzfeld sphere. At each stimulus intensity the recordings were repeated to ensure reproducibility (i.e., until two successive identical curves were obtained). All rabbits were sedated with Hypnorm (fentanylcitrate 0.315 mg/ml and fluanisone 10 mg/ml) during the examination.
Tissue preparation
The rabbits were euthanized by an intravenous overdose of barbiturates. The eyes were enucleated within one minute and fixed for 30 minutes in freshly prepared 4% phosphate-buffered formaldehyde, generated from paraformaldehyde (Merck, Darmstadt, Germany) at pH 7.4 in 0.1 M So¨rensen's phosphate buffer (primary and secondary NaHPO; Merck). The eyes were then transected at the oraciliaris retinae. The anterior segment, lens and vitreous body were discarded. The posterior segment was post-fixed in the same fixative for 3.5 h, at 4°C. The tissue was then rinsed and cryoprotected by transferring it stepwise through solutions of increasing concentrations of sucrose (10, 15 and 20%) in the So¨rensen's buffer. The eyecups were then divided into two parts by a vertical incision from the superior to the inferior retinal margins comprising the optic disc. The two halves were embedded in Yazulla media (30% egg albumen and 3% gelatine in water) and the sectioning (12l in the cryostat )21°C) started at the central part towards the peripheral part of the eye. The sections were collected on chrome alum coated slides, air dried, and stored at )20°C until used.
Immunohistochemistry
The sections were thawed and washed in 0.1 M sodium phosphate-buffered saline pH 7.2 (PBS) with 0.25% Triton X-100 (PBST). For diluting the primary and secondary antibodies, 1% bovine serum albumin was added in PBST. The sections were then incubated in the primary antibodies (Table 1) 
After rinsing, the slides were mounted in Vectashield (Vector Laboratories, Inc., Burlingham). The slides were examined using immunofluorescence imaging and photographed by a digital camera (Nikon Eclipse 800). The antibodies used for staining of retinal sections were GABA, GFAP, GAD, and vimentin.
Results
Medication
In all rabbits treated with vigabatrin the serum analyses, measured by high-performance liquid chromatography (HPLC), demonstrated an elevated drug concentration, while the controls had undetectable levels of the drug.
Electrophysiology
After 12-13 months of treatment the full-field ERG was reduced in all five rabbits treated with Table 2 . Table 2 ). The amplitudes of the rod isolated response, and of the combined cone-rod response to flashes of white light, both dark and light adapted, were not significantly affected during treatment. However, at the end of the treatment period, there was a statistically significant difference in the dark adapted cone b-wave amplitude between the treated animals and the controls (Wilcoxon signed-rank test, p = 0.043). This difference was consistent also 4-5 months after terminating treatment (Wilcoxon signedrank test, p = 0.043). The full-field ERG responses to all stimulations, from rabbit nr. 5 are shown in Figure 1 .
Histology
There was no significant difference in immunoreactivity for the four different antibodies between the treated animals and the controls. One of the treated animals had a slightly enhanced GFAP immunoreactivity, but this was seen also in one of the controls. We could not detect any changes in Mu¨ller cell morphology, or alterations in immunohistologic staining, of the type previously reported in rabbit retina during treatment with vigabatrin [14] .
Discussion
The antiepileptic drug vigabatrin is known to cause typical concentric visual field defects in at least 30-40% [7] [8] [9] of treated patients. Moreover it is well documented that vigabatrin medication gives electrophysiological changes such as a reduction in photopic b-wave amplitudes in the full-field ERG [8, [10] [11] [12] [13] . Similar reductions in cone b-wave amplitudes in the 30 Hz flicker ERG are also seen in rabbits receiving vigabatrin [14] . Several studies have demonstrated a reduced ERG also after discontinuation of medication [15, 17, 18, 21] . Duboc et al [27] have performed a study in rats, demonstrating a decrease in photopic ERG amplitudes in both single flash (by 40%) and in modified flicker responses; 5, 10 and 15 Hz (by 37%) after 45 days of vigabatrin treatment when compared to control animals. These pathological responses remain unchanged also after a 43-day recovery period without treatment.
The before mentioned observations are consistent with the results of the present study. Both during treatment and after 4-5 months without any medication, the treated rabbits show an unchanged reduction of the cone b-wave in the 30 Hz flicker ERG. These results indicate that vigabatrin causes irreversible changes in the photopic electroretinogram which can be interpreted as a dysfunction in one or more levels in the cone photoreceptor pathway. Neal et al. [28] have demonstrated GABA accumulation in retinal glial cells, mainly Mu¨ller cells, in rats receiving vigabatrin suggesting toxic levels of GABA as a cause of retinal damage. The increased Figure 1 . Full-field ERG from rabbit nr. 5 before and after treatment with vigabatrin. The ERG traces demonstrate that the rod response remains unaffected by vigabatrin, while the cone b-wave amplitude is significantly reduced by the drug, also after several months of wash-out.
concentration of GABA in rat retinal tissue has been confirmed in another investigation by Sills et al. [29] . They have also demonstrated a pronounced accumulation of vigabatrin in retina compared to brain tissue, considering this as a plausible cause of the visual field constriction reported in patients.
In the study by Duboc et al. [27] immunohistological examination of sectioned rat retina indicates severe alterations in retinal architecture both immediately after drug withdrawal and after a wash-out period of 45 days. PNA staining reveals disorganized cone outer and inner segments and a decrease in cone density throughout the whole retina. The peripheral parts were however most affected. In that study there was also enhanced GFAP expression in Mu¨ller glial cells around the areas of damaged cone photoreceptors. We have previously shown immunohistological changes in retina of rabbits examined during vigabatrin treatment [14] . These results suggest a pathological process in the Mu¨ller cells, which were short, stubby and fragmented with swollen end-feet in vimentin staining and also demonstrated enhanced GFAP immunoreactivity as a sign of tissue damage. There was also significant pathology of the IPL demonstrating poor staining with GAD and enhanced GABA-immunoreactivity.
In the present study we have performed the same immunohistochemical labelling process in retinal sections from rabbits euthanized 4-5 months after drug withdrawal. Immunofluorescens imaging shows no significant difference in immunoreactivity between treated animals and controls. This means that the pathological changes in Mu¨ller cells and IPL previously documented in rabbits receiving vigabatrin have been normalized and exist only during treatment. The electrophysiological changes, characterized by a decrease in the cone b-wave amplitude of the 30 Hz flicker ERG, are, however, still seen 4-5 months after withdrawal of medication, although the immunohistological signs of damaged Mu¨ller glial cells are no longer evident. Our findings indicate that the glial reaction might be reversible. However, there must be some form of retinal damage causing the remaining decrease in the photopic ERG. There seems to be a permanent retinal damage consistent with the irreversible visual field defects seen in patients. The results of Duboc et al. [27] suggest there is a probability that vigabatrin medication results in permanent damage to cone photoreceptors, which is in accordance with our observed alterations in the photopic ERG. At the time of analysis we did not have a specific marker for staining of cones. Further studies may reveal that both cones and Mu¨ller cells are involved in the pathogenesis of vigabatrin induced retinopathy.
We conclude that 5 months after terminating treatment with vigabatrin, the rabbit full-field ERG remains reduced in isolated cone b-wave amplitude, indicating that the vigabatrin induced retinal dysfunction may be irreversible. However, immunohistology of the inner retina and the glial cells is normal after a period without treatment, implying that the previously described changes in retinal morphology and glial cell activity are reversible, and probably exist only during treatment.
